| ［1］ 傅军民. 复发难治性非霍奇金淋巴瘤治疗进展［J］. 中国民族民间医药, 2013, 22(6): 8283. DOI: 10.3969/j.issn.10078517.2013.06.057.
［2］ Yim KL, Ashley S. Assessment of gemcitabine, cisplatin and methyl prednisolone (GEMP) combination treatment for nonHodgkin T cell lymphoma［J］. Med Oncol, 2012, 29(5): 35353539. DOI: 10.1007/s12032012030969.
［3］ 徐吉兵. 难治性非霍奇金淋巴瘤的治疗进展［J］. 中西医结合研究, 2012, 4(3): 160162. DOI: 10.3870/j.issn.16744616.2012.03.016.
［4］ Milone G, Martino M, Spadaro A, et al. Plerixafor ondemand combined with chemotherapy and granulocyte colonystimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs［J］. Br J Haematol, 2014, 164(1): l13123. DOI: 10.1111/bjh.12606.
［5］ Gharbaran R, Goy A, Tanaka T, et al. Fibroblast growth factor2 (FGF2) and syndecan1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients［J］. J Hematol Oncol, 2013, 6: 62. DOI: 10.1186/17568722662.
［6］ Di Renzo N, Brugiatelli M, Montanini A, et al. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive nonHodgkin′s lymphoma (NHL): results of a phase Ⅱ study conducted by the Gruppo Italiano per lo Studio dei Linfomi［J］. Leuk Lymphoma, 2006, 47(3): 473479. DOI: 10.1080/10428190500312295.
［7］ Papageorgiou ES, Tsirigotis P, Dimopoulos M, et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B celllymphoma: a phaseⅡ trial by the Hellenic Cooperative Oncology Group［J］. Eur J Hematol, 2005, 75(2): 124129. DOI: 10.1111/j.16000609.2005.00482.x.
［8］ 王莉. 左旋门冬酰胺酶联合GEMOX方案治疗鼻型NK/T淋巴瘤的疗效观察［J］. 黑龙江医学, 2014, 38(2): 163164. DOI: 10.3969/j.issn.10045775.2014.07.071.
［9］ 赵玲俊. 原发性骨淋巴瘤16例临床分析［J］. 中国继续医学教育, 2015, 7(9): 5354. DOI: 10.3969/j.issn.16749308.2015.09.046.
［10］ Sampol A, Rodriquez J, Galmés B, et al. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma［J］. Leuk Lymphoma, 2004, 45(6): 12891291. DOI: 10.1080/1042819032000159852.
［11］ 杨建良, 石远凯, 何小慧, 等. 吉西他滨联合奥沙利铂对多种化疗方案治疗失败后淋巴瘤患者的疗效及安全性评价［J］. 中华肿瘤杂志, 2014, 36(2): 137140. DOI: 10.3760/cma.j.issn.02533766.2014.02.014.
［12］ 杨新平. 吉西他滨联合奥沙利铂治疗弥漫性大B细胞淋巴瘤患者的临床疗效及安全性分析［J］. 当代医学, 2015, 21(26): 145146. DOI: 10.3969/j.issn.10094393.2015.26.099.
［13］ 屈敏, 杨国林. 吉西他滨联合奥沙利铂和地塞米松治疗复发/难治性非霍奇金淋巴瘤41例疗效观察［J］. 临床合理用药杂志, 2017, 10(8): 78, 21. DOI: 10.15887/j.cnki.131389/r.2017.08.004.
［14］ Cohen JB, Flowers CR. Optimal disease surveillance strategies in nonHodgkin lymphoma［J］. Hematology Am Soc Hematol Educ Program, 2014, 2014(1): 481487. DOI: 10.1182/asheducation2014.1.481.
［15］ 曾亮, 张永昌, 周春花, 等. GEMOX方案治疗32例复发难治性非霍奇金淋巴瘤疗效分析［J］. 肿瘤药学, 2014, 4(2): 139143. DOI: 10.3969/j.issn.20951264.2014.028. |
